CDD-2789

CDD-2789 is a highly selective small-molecule inhibitor targeting Activin receptor type 1 (ALK2, also known as ACVR1) . It blocks the SMAD1/5 signaling pathway mediated by ALK2/ALK1, thereby effectively suppressing downstream phosphorylation events induced by BMP and activin A. In the NanoBRET cellular model, CDD-2789 exhibits an inhibitory IC50 of 0.54 µM against ALK2. CDD-2789 holds promise for research on ALK2-related diseases, including diffuse intrinsic pontine glioma (DIPG), ependymoma, endometrial cancer, melanoma, non–small cell lung cancer, colorectal cancer, and pancreatic cancer[1].

Product Specifications

CAS Number

[3052084-77-9]

UNSPSC

12352005

Target

Anaplastic lymphoma kinase (ALK) ; TGF-beta/Smad; TGF-β Receptor

Related Pathways

Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; TGF-beta/Smad

Field of Research

Cancer

Smiles

COC1=C(OC)C=C(C2=NC(C=CC(C(NCCCN(C)C)=O)=C3)=C3N2C4CCC4)C=C1OC

Molecular Formula

C26H34N4O4

Molecular Weight

466.57

References & Citations

[1]Jimmidi R, et al. Discovery of highly potent and ALK2/ALK1 selective kinase inhibitors using DNA-encoded chemistry technology. Proc Natl Acad Sci U S A. 2024 Nov 19;121 (47) :e2413108121.